积极上进的小润
Lv3
240 积分
2023-04-14 加入
-
Type 2 diabetes mellitus
10天前
已完结
-
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
10天前
已完结
-
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
10天前
已完结
-
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
1个月前
已完结
-
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
1个月前
已完结
-
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
2个月前
已完结
-
Glucagon-like peptide 1 in health and disease
2个月前
已完结
-
Pharmacotherapy of obesity: Available medications and drugs under investigation
2个月前
已完结
-
Mechanisms, Pathophysiology, and Management of Obesity
2个月前
已完结
-
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
2个月前
已完结